SCOTTSDALE, Ariz., July 18, 2024 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (NASDAQ: LFST), one of the nation's largest providers of outpatient mental health care, will issue its second quarter 2024 earnings release before the market opens on Thursday, August 8, 2024. LifeStance will host a live earnings conference call to discuss second quarter results on August 8, 2024, at 8:30 a.m. Eastern Time. To participate in the call, please dial 1-800-715-9871, domestically, or 1-646-307-1963, internationall ...

TORONTO, July 18, 2024 (GLOBE NEWSWIRE) -- Lifeist Wellness Inc. ("Lifeist" or the "Company") (TSXV: LFST) (FRANKFURT: M5B0) (OTCMKTS: LFSWF), a health-tech company that leverages advancements in science and technology to build breakthrough ventures that transform human wellness, reports that its U.S. biosciences subsidiary Mikra Cellular Sciences Inc. ("Mikra") has unveiled its Big Summer Sale, with a free gift included with every order while supplies last. The sale is on now, and customers are invited to ...

The mean estimate comprises seven short-term price targets with a standard deviation of $0.94. While the lowest estimate of $7 indicates a 27.5% increase from the current price level, the most optimistic analyst expects the stock to surge 82.2% to reach $10. It's very important to note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts. However, an impressive consensus price target is not the only ...

Company Overview - Lifeist Wellness Inc. is a health-tech company focused on leveraging advancements in science and technology to create innovative ventures that enhance human wellness [3][12]. - The company operates through its U.S. biosciences subsidiary, Mikra Cellular Sciences Inc., which has filed a Natural Health Product License Application with Health Canada for its product CELLF 2.0 [12][6]. Product Details - CELLF 2.0 is a clinically validated formula designed to boost energy and focus at a cellular level while protecting against oxidative stress [14]. - The product contains a complete daily dose of Pyrroloquinoline Quinone (PQQ), Glutathione, and bioavailable CoQ10, formulated in a liposomal gel to ensure effective absorption [1][14]. - Recent studies indicate that PQQ improves cognitive function in both younger and older adults, enhancing memory and processing speed [7][13]. Research and Development - A 2023 study from Canadian and Chinese universities suggests that elevated glutathione levels in elderly individuals may correlate with increased healthspan and lifespan [2]. - A comprehensive review from an Italian medical university in 2023 highlights the significance of glutathione and its potential therapeutic applications in aging [8][11]. Market Position and Strategy - Lifeist aims to market CELLF 2.0 across Canada through various sales channels upon receiving the Natural Product Number from Health Canada [6]. - The company is committed to bringing scientifically backed natural products to market and anticipates expanding its customer base in 2024 [14][18].

SSC is a leading Canadian cannabis company which has successfully implemented innovative systems and operational methodologies resulting in six straight quarters of positive EBITDA and positive net income in Q1 2024. Lifeist shareholders are set to immediately benefit by having SSC support the operations of CannMart, deploying SSC's expertise from its existing operations, while enjoying a fee structure which ensures a minimum net revenue amount to be retained by CannMart each month. This arrangement will al ...

We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. Usually, a stock is considered oversold when its RSI reading falls below 30. Technically, every stock oscillates between being overbought and oversold irrespective of the quality of their fundamentals. And the beauty of RSI is that it helps you quickly and e ...

SCOTTSDALE, Ariz., May 23, 2024 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (NASDAQ: LFST), one of the nation's largest providers of outpatient mental health care, today announced that management will participate in the following upcoming investor conferences. UBS Healthcare Services Cape Cod Summit Participants: Dave Bourdon, CFO, and Monica Prokocki, VP of Finance and Investor Relations Date: Tuesday, June 4, 2024 Location: Chatham Bars Inn, Chatham, MA Note: No presentation due to event format; inv ...

Company Overview - LifeStance Health Group, Inc. is one of the largest providers of outpatient mental health care in the United States, focusing on both virtual and in-person services for various mental health conditions [3] - The company was founded in 2017 and employs approximately 6,800 mental health professionals, including psychiatrists, advanced practice nurses, psychologists, and therapists [3] - LifeStance operates across 33 states with more than 550 centers, aiming to improve access to affordable and personalized mental health care [3] Upcoming Investor Conferences - LifeStance management will participate in the UBS Healthcare Services Cape Cod Summit on June 4, 2024, with no formal presentation, only investor meetings [2] - The company will also present at the Goldman Sachs 45th Annual Healthcare Conference on June 10, 2024, at 10:00 a.m. Eastern time, with a potential live webcast of the presentation [2]

Core Points - LifeStance Health (NASDAQ:LFST) announced a secondary offering of 20 million shares priced at $6.25 each, leading to a decline in its stock price [1][2] - The offering is being conducted by a group of stockholders, and LifeStance Health will not receive any proceeds from this sale [2] - The offering price is significantly lower than the stock's previous closing price of $7.48, contributing to a 19.8% drop in LFST stock [3] Company Details - The underwriters for the offering include Morgan Stanley, Goldman Sachs & Co. LLC, and TPG Capital BD, LLC, who have a 30-day option to acquire an additional 3 million shares at the same offering price [2] - The secondary offering is entirely for the benefit of the selling shareholders, as LifeStance Health is not selling any shares itself [2]

Core Viewpoint - LifeStance Health Group, Inc. has announced a secondary underwritten public offering of 20,000,000 shares of its common stock at a price of $6.25 per share, with the offering expected to close around May 24, 2024 [1][2]. Company Overview - LifeStance, founded in 2017, is one of the largest providers of virtual and in-person outpatient mental health care in the United States, employing approximately 6,800 mental health professionals and operating over 550 centers across 33 states [5]. - The company's mission is to enhance access to affordable and personalized mental healthcare for individuals experiencing various mental health conditions [5]. Offering Details - The offering is being conducted under a shelf registration statement filed with the SEC, and the selling stockholders will receive all proceeds from the offering, while the company itself will not receive any funds [1][3]. - The underwriters have a 30-day option to purchase an additional 3,000,000 shares from the selling stockholders [1]. - Major financial institutions involved in the offering include Morgan Stanley, Goldman Sachs & Co. LLC, and TPG Capital BD, LLC as lead book-runners, with Jefferies, UBS Investment Bank, and William Blair as joint book-runners [2].